Financial Tearsheet

Company Overview

Vivos Inc. (OTCMKTS:RDGLD) is a Richland, Washington-based late stage development company engaged primarily in the development of brachytherapy devices for therapeutic applications. RDGL's focus is on transitioning to full operations upon receipt, if any, of FDA clearance for its patented brachytherapy cancer products. Brachytherapy uses radiation to destroy cancerous tumors by placing a radioactive isotope inside or next to the treatment area.

Since late 2013, RDGL has focused its resources on developing a proposed line of brachytherapy products and on endeavoring to secure FDA clearance with respect to the initial proposed brachytherapy product. RDGL's proposed brachytherapy products incorporate patented technology developed for Battelle Memorial Institute (“Battelle”) at Pacific Northwest National Laboratory, a leading research institute for government and commercial customers. Battelle has granted RDGL an exclusive license to patents covering these developments for manufacturing, processing and applications for medical isotopes (the “Battelle License”).

A prominent team of radiochemists, scientists and engineers, collaborating with strategic partners, including national laboratories, universities and private corporations, lead RDGL’s development efforts. RDGL has been recognized as a leader in the development of new isotope technologies by local, state and federal agencies.

The Company’s overall objective is to empower physicians, medical researchers, and ultimately, patients, by providing them with essential radionuclides that, until now, have not been practical or economical to produce, in an effort to detect, manage, and cure human disease, and improve the lives of patients. The Company’s shorter-term objective is to obtain regulatory approval for its brachytherapy products and to then commercialize those products.

Recent Financial News

Stock Performance

Today's Open 0.0750
Volume 743,497
Day Range 0.0650 - 0.0830
52 Week Range 0.0192 - 0.3168
Bid/Ask 0.0000 / 0.0000
Bid/Ask Size 0 X 0
Previous Close 0.0750
Market Cap 148.88 million
Shares Outstanding 1.97 billion
Dividend/Yield 0.0000 / 0.0000%
EPS (TTM) N/A
P/E Ratio (TTM) N/A

Recent XBRL Filings

Filing Date Form Type Description View
Jun 24, 2019 10-Q/A Quarterly report (Amendment) htmlhtml   pdfpdf   xbrlxbrl  
May 13, 2019 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Mar 25, 2019 10-K Annual report htmlhtml   pdfpdf   xbrlxbrl  
Nov 14, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  
Aug 20, 2018 10-Q Quarterly report htmlhtml   pdfpdf   xbrlxbrl  

Management Team

Dr. Mike Korenko, President • CEO

Dr. David J. Swanberg, Chief Technical Manager

Dr. Donald A. Ludwig, Director of Special Projects

Dr. Nigel R. Stevenson, Chief Science Officer

Board of Directors

Dr. Carlton Cadwell, Chairman • Director

Dr. Mike Korenko, President • CEO • Director